Medicus Pharma Ltd. (MDCX)
| Market Cap | 17.65M -64.2% |
| Revenue (ttm) | n/a |
| Net Income | -51.22M |
| EPS | -2.37 |
| Shares Out | 55.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,583,159 |
| Open | 0.3259 |
| Previous Close | 0.3377 |
| Day's Range | 0.3200 - 0.3400 |
| 52-Week Range | 0.2500 - 3.6900 |
| Beta | -0.50 |
| Analysts | Strong Buy |
| Price Target | 5.67 (+1,671.88%) |
| Earnings Date | May 14, 2026 |
About MDCX
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was inco... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MDCX stock is "Strong Buy." The 12-month stock price target is $5.67, which is an increase of 1,671.88% from the latest price.
News
Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA
Medicus Pharma (MDCX) announced the submission of a Rare Pediatric Disease Designation request to the FDA for SkinJect, the company’s investigational doxorubicin-containing microneedle array patch, fo...
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs ...
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as a potential long-acting precision medicine...
Medicus Pharma submits substantial modification application through EU CTIS
Medicus Pharma (MDCX) announced the submission of a substantial modification application through the European Union Clinical Trials Information System, or CTIS, supporting the planned Phase 2b study o...
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity European regulatory filing s...
Medicus Pharma submits Protocol SKNJCT-005 to the FDA
Medicus Pharma (MDCX) announced the submission of Protocol SKNJCT-005 to the FDA under the company’s existing investigational new drug, or IND, application, for SkinJect into registrational developmen...
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
PHILADELPHIA, June 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs ...
Medicus Pharma Announces $22 Million Non-Dilutive Financing
Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years Financing Provides Immediate Growth Capital t...
Medicus Pharma reports Q1 EPS (31c), consensus (22c)
“During the first quarter of 2026, Medicus continued to execute on its transformation into a diversified clinical-stage biotechnology company, highlighted by expanded positive Phase 2 SkinJect data, a...
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives Company Advances SkinJect® and Teverelix® Clinical...
Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis
Medicus Pharma (MDCX) announced results from a pre-specified expanded dataset analysis demonstrating positive dose response from its Phase 2 SKNJCT-003 study evaluating safety and efficacy of doxorubi...
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs o...
Medicus Pharma meets with lawmakers to support SkinJect designations
Medicus Pharma (MDCX) announced that CEO Raza Bokhari, along with the Medicus leadership team, conducted a series of meetings on Capitol Hill with senior lawmakers across key healthcare committees to…
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant Disease Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients w...
Medicus Pharma initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $9 price target The firm projects growing revenue from the company’s doxorubicin- microneedle array in basal cell…
Medicus Pharma submits ODD application to U.S. FDA for SkinJect
Medicus Pharma (MDCX) announced the submission of an Orphan Drug Designation, ODD, application to the U.S. Food and Drug Administration for SkinJect, D-MNA, for the treatment of basal cell carcinoma,…
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinoma Targets rare, high-burden genetic condition with no ...
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
Updated Safety, Efficacy, and Clinical Data Supports Teverelix as Potentially the First Long-Acting Injectable GnRH Antagonist Across Multiple Indications in Women's Health Updated Safety, Efficacy, a...
Medicus Pharma enters media partnership with New to The Street
Medicus Pharma (MDCX) entered into a 12-part, one-year strategic media agreement with New to The Street to expand its national and international visibility across television, digital, and outdoor plat...
Medicus Pharma submits clinical study design to FDA for Teverelix
Medicus Pharma (MDCX) announced the company has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, its investigational GnRH antagonist, for the prevention of recurrent acut...
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market Mechanism-Driven Study Design Focu...
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancer Provides guidance on interpretation of Topline dataset and confirms focus ...
Medicus Pharma reports principal investigator validation of Phase 2 data
Medicus Pharma (MDCX) reported independent clinical validation of its Phase 2 SkinJect dataset from Dr. Babar Rao, principal investigator of the SKNJCT-003 study. “In my view as principal investigator...
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer Dr. Babar Rao highlights clinically meaningful outco...
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer 200µg Cohort at Day 57 Dataset suggests m...